A persimmon leaf-derived polysaccharide fraction, a preparation method thereof, and use thereof, the persimmon leaf-derived polysaccharide fraction including, based on the total weight of the polysaccharide fraction, 70-90 wt % of neutral sugar and 10-30 wt % of uronic acid.

A persimmon leaf-derived polysaccharide fraction, a preparation method thereof, and use thereof, the persimmon leaf-derived polysaccharide fraction including, based on the total weight of the polysaccharide fraction, 70-90 wt % of neutral sugar and 10-30 wt % of uronic acid.

Disclosed herein are compositions and methods for modulating a macrolide antimicrobial, modulating an immune function, increasing the effectiveness of an antibiotic, and/or increasing the number and effectiveness of alveolar macrophages in treating a vertebrate animal. The method comprises feeding to the animal a feed composition comprising (1, 3), (1, 6), beta-glucans and optionally mannans to increase the number of alveolar macrophage cells, and administering a macrolide antibiotic to the animal.

Disclosed herein are compositions and methods for modulating a macrolide antimicrobial, modulating an immune function, increasing the effectiveness of an antibiotic, and/or increasing the number and effectiveness of alveolar macrophages in treating a vertebrate animal. The method comprises feeding to the animal a feed composition comprising (1, 3), (1, 6), beta-glucans and optionally mannans to increase the number of alveolar macrophage cells, and administering a macrolide antibiotic to the animal.

Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.

The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.

Hot melt extrusion is disclosed as a process for forming vaginal drug delivery films. The methods involve extruding a composition comprising one or more active pharmaceutical ingredients and one or more polymer carriers at an elevated temperature through a die to thereby provide the film. Films prepared by hot melt extrusion are also described.

Hot melt extrusion is disclosed as a process for forming vaginal drug delivery films. The methods involve extruding a composition comprising one or more active pharmaceutical ingredients and one or more polymer carriers at an elevated temperature through a die to thereby provide the film. Films prepared by hot melt extrusion are also described.